Increase in muscle mitochondrial biogenesis does not prevent muscle loss but increased tumor size in a mouse model of acute cancer-induced cachexia

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Wang, Xiao ^a   Pickrell, Alicia M ^a   Zimmers, Teresa A ^a,b,c   Moraes, Carlos T ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; INTERLEUKIN 6; PPARGC1A PROTEIN, MOUSE; PRIMER DNA; TRANSACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOGENESIS; CACHEXIA; CANCER CACHEXIA; CONTROLLED STUDY; FEMALE; LEWIS CARCINOMA; MOUSE; MUSCLE ATROPHY; MUSCLE METABOLISM; MUSCLE MITOCHONDRION; NONHUMAN; PRIMARY PREVENTION; PROTEIN EXPRESSION; SKELETAL MUSCLE; TUMOR VOLUME; ANALYSIS OF VARIANCE; ANIMAL; BLOOD; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALIA; MURINAE; MUS; MUS MUSCULUS;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CACHEXIA; CARCINOMA, LEWIS LUNG; CYTOKINES; DNA PRIMERS; INTERLEUKIN-6; MICE; MICE, TRANSGENIC; MITOCHONDRIA, MUSCLE; MUSCLE, SKELETAL; MUSCULAR ATROPHY; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY; TRANS-ACTIVATORS;

EID: 84863268283     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033426     Document Type: Article

References (29)

1. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, et al. (2008) Cachexia: a new definition. Clinical nutrition 27: 793-799.
2. Martignoni ME, Kunze P, Friess H, (2003) Cancer cachexia. Molecular cancer 2: 36.
3. Esper DH, Harb WA, (2005) The cancer cachexia syndrome: a review of metabolic and clinical manifestations. Nutrition in clinical practice: official publication of the American Society for Parenteral and Enteral Nutrition 20: 369-376.
4. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, et al. (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69: 491-497.
5. Deans C, Wigmore SJ, (2005) Systemic inflammation, cachexia and prognosis in patients with cancer. Current opinion in clinical nutrition and metabolic care 8: 265-269.
6. Fearon KC, Voss AC, Hustead DS, (2006) Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. The American journal of clinical nutrition 83: 1345-1350.
7. White JP, Baltgalvis KA, Puppa MJ, Sato S, Baynes JW, et al. (2011) Muscle oxidative capacity during IL-6-dependent cancer cachexia. American journal of physiology Regulatory, integrative and comparative physiology 300: R201-211.
8. Crouser ED, (2010) Peroxisome proliferator-activated receptors gamma coactivator-1alpha: master regulator of mitochondrial biogenesis and survival during critical illness? American journal of respiratory and critical care medicine 182: 726-728.
9. Bing C, Brown M, King P, Collins P, Tisdale MJ, et al. (2000) Increased gene expression of brown fat uncoupling protein (UCP)1 and skeletal muscle UCP2 and UCP3 in MAC16-induced cancer cachexia. Cancer research 60: 2405-2410.
10. Tisdale MJ, (2000) Metabolic abnormalities in cachexia and anorexia. Nutrition 16: 1013-1014.
11. Remels AH, Gosker HR, Schrauwen P, Hommelberg PP, Sliwinski P, et al. (2010) TNF-alpha impairs regulation of muscle oxidative phenotype: implications for cachexia? The FASEB journal: official publication of the Federation of American Societies for Experimental Biology 24: 5052-5062.
12. MacDonald N, (2007) Cancer cachexia and targeting chronic inflammation: a unified approach to cancer treatment and palliative/supportive care. J Support Oncol 5: 157-162; discussion 164-156, 183.
13. Lin J, Wu H, Tarr PT, Zhang CY, Wu Z, et al. (2002) Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 418: 797-801.
14. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, et al. (1999) Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98: 115-124.
15. Liang H, Ward WF, (2006) PGC-1alpha: a key regulator of energy metabolism. Advances in physiology education 30: 145-151.
16. Scarpulla RC, (2008) Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiological reviews 88: 611-638.
17. Wenz T, Diaz F, Spiegelman BM, Moraes CT, (2008) Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell metabolism 8: 249-256.
18. Wenz T, Rossi SG, Rotundo RL, Spiegelman BM, Moraes CT, (2009) Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic disease during aging. Proceedings of the National Academy of Sciences of the United States of America 106: 20405-20410.
19. Sandri M, Lin J, Handschin C, Yang W, Arany ZP, et al. (2006) PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proceedings of the National Academy of Sciences of the United States of America 103: 16260-16265.
20. Smith KL, Tisdale MJ, (1993) Increased protein degradation and decreased protein synthesis in skeletal muscle during cancer cachexia. British journal of cancer 67: 680-685.
21. Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, et al. (1994) Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. The Journal of clinical investigation 93: 2379-2386.
22. Garcia-Lorda P, Serrano P, Jimenez-Exposito MJ, Fraile J, Bullo M, et al. (2000) Cytokine-driven inflammatory response is associated with the hypermetabolism of AIDS patients with opportunistic infections. JPEN Journal of parenteral and enteral nutrition 24: 317-322.
23. Wenz T, Diaz F, Hernandez D, Moraes CT, (2009) Endurance exercise is protective for mice with mitochondrial myopathy. Journal of applied physiology 106: 1712-1719.
24. Safdar A, Little JP, Stokl AJ, Hettinga BP, Akhtar M, et al. (2011) Exercise increases mitochondrial PGC-1alpha content and promotes nuclear-mitochondrial cross-talk to coordinate mitochondrial biogenesis. The Journal of biological chemistry 286: 10605-10617.
25. Pedersen BK, Akerstrom TC, Nielsen AR, Fischer CP, (2007) Role of myokines in exercise and metabolism. Journal of applied physiology 103: 1093-1098.
26. Tisdale MJ, (2002) Cachexia in cancer patients. Nature reviews Cancer 2: 862-871.
27. Pedersen BK, Febbraio MA, (2008) Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiological reviews 88: 1379-1406.
28. Barrientos A, (2002) In vivo and in organello assessment of OXPHOS activities. Methods 26: 307-316.
29. Schmittgen TD, Livak KJ, (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108.